Freeport-McMoRan Inc. engages in the mining of mineral properties in North America, South America, and Indonesia. It primarily explores for copper, gold, molybdenum, silver, and other metals.

Its pipeline also includes CFTX-1334, an AT2 receptor antagonist for neuropathic pain that was partnered with Eli Lilly in a $590m deal last year. Other investors in the round included Driehaus ...

To sign up for Becker's ASC Review E-Newsletter or any of our other E-Newsletters, click here. If you are experiencing difficulty receiving our newsletters, you may ...